EGH1 Antibody

What is GH1 and what are its common alternative names in scientific literature?

Growth Hormone 1 (GH1) is a protein encoded by the GH1 gene in humans with an expected molecular mass of approximately 24.8 kDa. The protein is commonly known by several synonyms in research literature, including somatotropin, GH, GH-N, GHB5, GHN, and growth hormone B5. These alternative designations may appear across different publications and databases, so researchers should be aware of all nomenclature variations when conducting literature searches . GH1 is primarily produced by somatotrophs in the anterior pituitary gland and plays crucial roles in growth, cell reproduction, and regeneration.

What are the main isoforms of GH1 and how do they impact antibody selection?

There are five reported isoforms of the GH1 protein that researchers should consider when selecting antibodies for specific applications. These isoforms arise from alternative splicing of the GH1 gene transcript and post-translational modifications . The presence of multiple isoforms creates challenges for researchers, as antibodies may exhibit differential recognition patterns depending on the epitopes targeted. When designing experiments, researchers should carefully evaluate the specificity of antibodies for particular isoforms and consider whether their research question requires detection of specific variants or all isoforms collectively.

What applications are GH1 antibodies commonly validated for in research settings?

GH1 antibodies are validated for numerous research applications including Western blotting (WB), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and immunoprecipitation (IP) . The suitability of a particular antibody for each application varies significantly based on the antibody's characteristics. For example, some antibodies may perform exceptionally well in ELISA but poorly in IHC due to differences in how the epitopes are presented in various experimental conditions. Researchers should verify application-specific validation data before selecting a GH1 antibody for their experiments.

How is antibody specificity for GH1 validated to ensure experimental reliability?

Validating antibody specificity for GH1 requires multiple complementary approaches. The gold standard for specificity testing includes human genome-wide protein arrays to assess cross-reactivity against related proteins. For example, the AE00179 monoclonal antibody was tested against more than 19,000 full-length human proteins including closely related proteins (CSH1, CSHL1, and CSH2) and demonstrated no cross-reactivity with these structurally similar hormones .

Researchers should look for antibodies with Z-score data that indicate strong binding to the intended target with minimal binding to other proteins. An antibody is typically considered specific when it has an S-score (the difference between successive Z-scores when arranged in descending order) of at least 2.5 . Additional validation methods include knockout/knockdown controls, using multiple antibodies targeting different epitopes, and peptide competition assays to confirm specificity in the experimental system of interest.

What are the optimal sample preparation protocols for GH1 detection in human pituitary tissue?

For immunohistochemical detection of GH1 in human pituitary tissue, formaldehyde fixation followed by paraffin embedding represents the standard approach. Based on validated protocols, epitope retrieval requires boiling at pH 6.0 for 10-20 minutes followed by a 20-minute cooling period to optimize antigen accessibility . For antibody incubation, a concentration of 1-3 μg/ml with a 30-minute incubation at room temperature has demonstrated effective staining of somatotrophs in human anterior pituitary sections .

Signal development using 3,3'-diaminobenzidine (DAB) with horseradish peroxidase (HRP) polymer systems offers excellent sensitivity and stable staining. Researchers should also include appropriate controls, particularly negative controls (omitting primary antibody) and positive controls (tissues known to express GH1) to validate staining specificity. For advanced applications, dual immunofluorescence labeling with markers of other pituitary cell types can help confirm cell-specific expression patterns.

How do monoclonal and polyclonal GH1 antibodies differ in performance and application suitability?

Monoclonal and polyclonal GH1 antibodies exhibit distinct characteristics that influence their experimental utility. Monoclonal antibodies, like AE00179 (mouse IgG2b, kappa), recognize specific epitopes on the GH1 protein, offering high reproducibility and reduced batch-to-batch variation . These properties make them ideal for experiments requiring consistent results over time or across multiple laboratories.

For quantitative applications like ELISA, paired monoclonal antibodies recognizing different epitopes often provide optimal specificity and sensitivity. For immunohistochemistry, the choice depends on the fixation method, with some epitopes being more resistant to fixation-induced conformational changes than others.

What strategies can address cross-reactivity issues with structurally similar hormones?

Cross-reactivity with related hormones presents a significant challenge when working with GH1 antibodies due to structural similarities with chorionic somatomammotropin hormone 1 (CSH1), chorionic somatomammotropin hormone-like 1 (CSHL1), and chorionic somatomammotropin hormone 2 (CSH2). To address this challenge, researchers should:

• Select antibodies that have been explicitly tested against these related proteins, such as those validated on human protein arrays

• Perform pre-absorption controls with recombinant related proteins to verify specificity within the experimental system

• Include appropriate tissue controls (placental tissue expresses CSH1/CSH2, while normal pituitary expresses GH1)

• Consider using antibodies targeting unique regions of GH1 that are absent in related proteins

• Employ complementary detection methods based on different principles (e.g., mass spectrometry) to confirm antibody-based findings

For particularly challenging applications, competitive binding assays can help determine the relative affinity of an antibody for GH1 versus related hormones, enabling more precise interpretation of experimental results.

How can researchers optimize epitope retrieval methods for GH1 detection in FFPE tissues?

Optimizing epitope retrieval for GH1 detection in formalin-fixed paraffin-embedded (FFPE) tissues requires systematic assessment of key variables. The recommended protocol involving boiling at pH 6.0 for 10-20 minutes provides a starting point , but researchers should consider testing:

• Different pH conditions (3.0, 6.0, and 9.0) to accommodate epitope characteristics

• Various retrieval durations (10, 20, or 30 minutes)

• Heat sources (microwave, pressure cooker, or water bath) that may affect retrieval efficiency

• Enzymatic retrieval methods (trypsin, proteinase K) as alternatives for certain epitopes

• Combination methods that employ both heat and enzymatic treatment for particularly challenging samples

A titration matrix examining these variables systematically can identify optimal conditions for specific antibody-tissue combinations. Importantly, researchers should maintain consistent retrieval conditions throughout a study to ensure comparable results across samples.

What essential controls should be implemented when using GH1 antibodies in Western blotting?

Western blotting with GH1 antibodies requires rigorous controls to ensure reliable interpretation of results. Essential controls include:

• Positive control: Recombinant GH1 protein or extracts from tissues known to express GH1 (pituitary) at the expected molecular weight of approximately 24.8 kDa

• Negative control: Tissue extracts from tissues that do not express GH1 or from GH1-knockout models

• Antibody controls:

  • Primary antibody omission

  • Isotype control (same isotype and concentration as the primary antibody)

  • Peptide competition assay (pre-incubation of antibody with immunizing peptide)

• Loading control: Probing for housekeeping proteins (β-actin, GAPDH) to normalize GH1 expression

• Molecular weight verification: Using multiple antibodies targeting different epitopes to confirm specificity of the observed band

Researchers should also be aware of potential post-translational modifications that may alter the apparent molecular weight of GH1 in Western blots compared to the predicted 24.8 kDa. Detailed documentation of sample preparation, blocking conditions, antibody dilutions, and detection methods is essential for reproducibility.

How does antibody isotype selection impact functional studies of GH1?

The antibody isotype significantly influences functional studies of GH1, particularly when investigating mechanisms beyond simple antigen detection. IgG1 antibodies, for example, can potentially engage in antibody-dependent cellular cytotoxicity (ADCC) through interaction with Fc receptors on monocytes, macrophages, and neutrophils (FcγRI, FcγRIIa, FcγRIIIa) . This functional capacity must be considered when designing experiments, as it may introduce variables beyond simple antigen binding.

Different isotypes exhibit varying abilities to fix complement, cross placental barriers, and interact with Fc receptors. For mouse monoclonal antibodies against GH1, IgG2b isotypes (like AE00179) offer good specificity with moderate complement activation properties . When designing neutralization experiments or cell-based assays, these isotype-specific effector functions may influence results. Researchers should select isotypes consistent with their experimental goals and include appropriate controls to account for isotype-mediated effects.

What approaches can detect specific GH1 isoforms when studying differential expression patterns?

Detecting specific GH1 isoforms presents significant challenges due to their structural similarities. Effective strategies include:

• Epitope-specific antibodies: Developing antibodies against unique regions that differentiate isoforms

• Two-dimensional electrophoresis: Separating isoforms by both isoelectric point and molecular weight before immunodetection

• Mass spectrometry: Identifying isoform-specific peptide fragments after immunoprecipitation

• RNA analysis: Correlating protein findings with splice variant expression using RT-PCR or RNA-Seq

• Combined immunoprecipitation-mass spectrometry: Enriching GH1 proteins followed by peptide fingerprinting to distinguish isoforms

When designing isoform-specific detection methods, researchers should validate their approach using recombinant proteins representing each isoform. Careful consideration of sample preparation is also critical, as certain extraction methods may preferentially recover specific isoforms, potentially biasing results.

How can researchers quantitatively assess GH1 levels using antibody-based methods?

Quantitative assessment of GH1 levels using antibody-based methods requires careful selection of techniques and standards:

• Sandwich ELISA: Using capture and detection antibodies recognizing different epitopes provides high specificity and sensitivity. Multiple commercial antibodies are validated for ELISA applications with human GH1 .

• Quantitative Western blotting: With appropriate standard curves using recombinant GH1 protein, densitometric analysis can provide semi-quantitative results.

• Automated immunoassay platforms: Clinical-grade systems offer high reproducibility with validated antibody pairs.

• Single-cell analysis: Mass cytometry or quantitative immunofluorescence can assess GH1 expression at the cellular level with appropriate calibration.

For all quantitative applications, researchers should:

• Include a full standard curve with recombinant GH1

• Validate the linear range of detection

• Assess recovery rates from the sample matrix

• Determine inter- and intra-assay coefficients of variation

• Confirm specificity using competitive binding with unlabeled antibodies

These practices ensure that quantitative results accurately reflect biological GH1 levels rather than technical artifacts.